JNJ-78934804 vs risankizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline

JNJ-78934804

Developed by Johnson & Johnson

Phase 3 in Ulcerative ColitisCo-antibody combination (guselkumab + golimumab, SC)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2028 · NCT07577856 (registry estimate)

No aligned efficacy figure on record for this race.

risankizumab · Skyrizi

Marketed by AbbVie and partners

Approved in Ulcerative Colitismonoclonal antibody
Reliable signal

NCT03398148 · Phase 2/3 · completed

Design meets the 'strong' test: randomized, double-blind (participant and investigator masked), placebo-controlled, large adequately powered sample (n=1555 treated), hard clinical/endoscopic composite endpoint (Adapted Mayo Score remission including endoscopic subscore), and the primary comparison was statistically significant in the favorable direction for all randomized dose arms in both substudies.

Next expected readout: August 2027 · NCT06880744 (registry estimate)

Reported efficacy

clinical remission + endoscopic improvement met (met)

Result source: INSPIRE/COMMAND

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointJNJ-78934804risankizumab
Clinical remission (induction)—Trial running · NCT0757785620.3% vs 6.2%+14.1 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
4 other results
  • 12.4% vs 1.7% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · primary NCT03398148
  • 9.8% vs 1.7% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148
  • 10.3% vs 1.7% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · primary NCT03398148
  • 11.5% vs 1.7% 600 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148
Clinical remission (maintenance)—Trial running · NCT07577856—Trial running · NCT03398135
Clinical response (induction)—Trial running · NCT0757785664.3% vs 35.7%+28.6 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
9 other results
  • 52.2% vs 30.5% 1200 mg IV · wk 4 · n 650 · Phase 2/3 · secondary NCT03398148
  • 46.2% vs 20% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · secondary NCT03398148
  • 43.5% vs 25% 1800 mg IV · wk 4 · n 340 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 20% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 25% 1200 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148
  • 53.4% vs 20% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · secondary NCT03398148
  • 37.9% vs 25% 1800 mg IV · wk 4 · n 58 · Phase 2/3 · secondary NCT03398148
  • 42.6% vs 20% 600 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 32.8% vs 25% 600 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148
Endoscopic improvement (induction)—Trial running · NCT0757785636.5% vs 12.1%+24.4 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
Corticosteroid-free remission (maintenance)—Trial running · NCT07577856—Trial running · NCT03398135

Clinical remission (induction)

JNJ-78934804
—Trial running · NCT07577856
risankizumab
20.3% vs 6.2%+14.1 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
4 other results
  • 12.4% vs 1.7% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · primary NCT03398148
  • 9.8% vs 1.7% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148
  • 10.3% vs 1.7% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · primary NCT03398148
  • 11.5% vs 1.7% 600 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148

Clinical remission (maintenance)

JNJ-78934804
—Trial running · NCT07577856
risankizumab
—Trial running · NCT03398135

Clinical response (induction)

JNJ-78934804
—Trial running · NCT07577856
risankizumab
64.3% vs 35.7%+28.6 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
9 other results
  • 52.2% vs 30.5% 1200 mg IV · wk 4 · n 650 · Phase 2/3 · secondary NCT03398148
  • 46.2% vs 20% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · secondary NCT03398148
  • 43.5% vs 25% 1800 mg IV · wk 4 · n 340 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 20% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 25% 1200 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148
  • 53.4% vs 20% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · secondary NCT03398148
  • 37.9% vs 25% 1800 mg IV · wk 4 · n 58 · Phase 2/3 · secondary NCT03398148
  • 42.6% vs 20% 600 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 32.8% vs 25% 600 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148

Endoscopic improvement (induction)

JNJ-78934804
—Trial running · NCT07577856
risankizumab
36.5% vs 12.1%+24.4 vs placebo1200 mg IV · wk 12 · n 650NCT03398148

Corticosteroid-free remission (maintenance)

JNJ-78934804
—Trial running · NCT07577856
risankizumab
—Trial running · NCT03398135
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

JNJ-78934804: no structured comparison results are available for Ulcerative Colitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. JNJ-78934804: 0 of 4 rows · risankizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricrisankizumab
Dropout rate
4.9%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 13 more results
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1.7%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
10.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
9.8%600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
Discontinued due to AEs
3.3%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 13 more results
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
0%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
2.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
3.3%600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
Serious AEs
6.6%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 13 more results
2.6%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1.5%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
2.3%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
9.9%360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1.4%360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.5%180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
5.6%180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.6%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
2.7%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
9.7%600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
Most frequent reported AEs
1200 mg IV
colitis ulcerative 4.9% (placebo 8.5%)
headache 4.9% (placebo 5.1%)
nasopharyngitis 4.9% (placebo 6.8%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 12 more results
1200 mg IV
covid-19 4.6% (placebo 0%)
anaemia 3.2% (placebo 3.4%)
headache 2.9% (placebo 5.1%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1200 mg IV
covid-19 5.9% (placebo 0%)
headache 2.9% (placebo 5.1%)
anaemia 1.5% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1200 mg IV
covid-19 5.7% (placebo 0%)
anaemia 2.9% (placebo 3.4%)
colitis ulcerative 1.7% (placebo 8.5%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
360 mg SC
nasopharyngitis 8.5% (placebo 6.8%)
headache 7% (placebo 5.1%)
colitis ulcerative 4.2% (placebo 8.5%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
360 mg SC
anaemia 8.5% (placebo 3.4%)
covid-19 8.5% (placebo 0%)
headache 8.5% (placebo 5.1%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
180 mg SC
headache 2.8% (placebo 5.1%)
anaemia 1.4% (placebo 3.4%)
nasopharyngitis 1.4% (placebo 6.8%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
180 mg SC
covid-19 5.6% (placebo 0%)
colitis ulcerative 4.2% (placebo 8.5%)
anaemia 2.8% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
nasopharyngitis 8.6% (placebo 6.8%)
headache 6.9% (placebo 5.1%)
anaemia 1.7% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
nasopharyngitis 7% (placebo 6.8%)
headache 6.5% (placebo 5.1%)
anaemia 3.5% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
nasopharyngitis 10.8% (placebo 6.8%)
anaemia 2.7% (placebo 3.4%)
colitis ulcerative 2.7% (placebo 8.5%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
dry skin 5.6% (placebo 0%)
headache 5.6% (placebo 5.1%)
nasopharyngitis 5.6% (placebo 6.8%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
600 mg IV
nasopharyngitis 8.1% (placebo 6.8%)
bronchitis 6.5% (placebo 0%)
dry skin 3.2% (placebo 0%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

risankizumab

Clinical Remission 9.8% (n=61) vs 1.7% (n=60) placebo @ 12wk1200 mg IV
responder rate · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 6 Participants as posted
show 4 more results
20.3% (n=650) vs 6.2% (n=325) placebo @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
10.3% (n=58) vs 1.7% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 6 Participants as posted
12.4% (n=340) vs 1.7% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 42 Participants as posted
11.5% (n=61) vs 1.7% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 7 Participants as posted
Endoscopic Improvement 13.1% (n=61) vs 5% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 8 Participants as posted
show 3 more results
15.5% (n=58) vs 5% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 9 Participants as posted
17.9% (n=340) vs 5% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 61 Participants as posted
24.6% (n=61) vs 5% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 15 Participants as posted
Clinical Response 45.9% (n=61) vs 20% (n=60) placebo @ 12wk1200 mg IV
responder rate · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 28 Participants as posted
show 9 more results
45.9% (n=61) vs 25% (n=60) placebo @ 4wk*1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 28 Participants as posted
64.3% (n=650) vs 35.7% (n=325) placebo @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
52.2% (n=650) vs 30.5% (n=325) placebo @ 4wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
53.4% (n=58) vs 20% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 31 Participants as posted
46.2% (n=340) vs 20% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 157 Participants as posted
37.9% (n=58) vs 25% (n=60) placebo @ 4wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 22 Participants as posted
43.5% (n=340) vs 25% (n=60) placebo @ 4wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 148 Participants as posted
42.6% (n=61) vs 20% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 26 Participants as posted
32.8% (n=61) vs 25% (n=60) placebo @ 4wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 20 Participants as posted
Endoscopic Remission 4.9% (n=61) vs 0% (n=60) placebo @ 12wk1200 mg IV
responder rate · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 3 Participants as posted
show 4 more results
10.6% (n=650) vs 3.4% (n=325) placebo @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.6% (n=58) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 5 Participants as posted
6.5% (n=340) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 22 Participants as posted
8.2% (n=61) vs 0% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 5 Participants as posted
UC-related Hospitalization 6.6% (n=61) vs 8.3% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 4 Participants as posted
show 3 more results
5.2% (n=58) vs 8.3% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 3 Participants as posted
5.6% (n=340) vs 8.3% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 19 Participants as posted
9.8% (n=61) vs 8.3% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 6 Participants as posted
HEMR 3.3% (n=61) vs 0% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 2 Participants as posted
show 3 more results
1.7% (n=58) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 1 Participants as posted
2.9% (n=340) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 10 Participants as posted
4.9% (n=61) vs 0% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 3 Participants as posted
UC-SQ -15.6 vs -7.4 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 3 more results
-15.1 vs -7.4 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
-17.1 vs -7.4 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
-13.8 vs -7.4 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
IBDQ 40.3 vs 20.1 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 4 more results
42.6 vs 24.3 placebo score @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
40 vs 20.1 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
49.5 vs 20.1 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
37.4 vs 20.1 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
SF-36 PCS 6.35 vs 3.904 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 3 more results
6.296 vs 3.904 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.719 vs 3.904 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
5.112 vs 3.904 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
SF-36 MCS 7.284 vs 3.094 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 3 more results
5.442 vs 3.094 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.777 vs 3.094 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
6.756 vs 3.094 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
FACIT-Fatigue 9 vs 3.7 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 4 more results
7.9 vs 3.3 placebo score @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.3 vs 3.7 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
10.7 vs 3.7 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.6 vs 3.7 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
UC-related Surgery 0% (n=61) vs 0% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 0 Participants as posted
show 3 more results
0% (n=58) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 0 Participants as posted
2.1% (n=340) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 7 Participants as posted
1.6% (n=61) vs 0% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 1 Participants as posted

+ 8 further endpoints in the CSV export.

Crohn's Disease

Shared mechanism: IL-23 p19 · full Crohn's Disease pipeline

JNJ-78934804

Developed by Johnson & Johnson

Phase 3 in Crohn's DiseaseCo-antibody combination (guselkumab + golimumab, SC)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07577843 (registry estimate)

No aligned efficacy figure on record for this race.

risankizumab · Skyrizi

Marketed by AbbVie and partners

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT03104413 · Phase 3 · completed

Design meets the 'strong' test: randomized, double-blind, placebo-controlled, adequately powered (n~600), with a hard endoscopic co-primary endpoint (SES-CD response) plus CDAI clinical remission, and both primary endpoint comparisons were statistically significant in the favorable direction for both doses vs placebo.

Next expected readout: March 2027 · NCT06063967 (registry estimate)

Reported efficacy

US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12); US Specific: Percentage of Participants With Endoscopic Response (Week 12); Global Outside of US: Percentage of Participants With Clinical Remission (Week 12); Global Outside of US: Percentage of Participants With Endoscopic Response (Week 12): US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (Week 12): Placebo (Induction Period 1) 19.8% (95% CI 14.1-25.5) vs Risankizumab 600mg (Induction Period 1) 42.0% (95% CI 34.9-49.0) vs Risankizumab 1200mg (Induction Period 1) 40.3% (95% CI 33.4-47.3); p=<0.001 (Placebo (Induction Period 1) vs Risankizumab 600mg (Induction Period 1)), p=< 0.001 (Placebo (Induction Period 1) vs Risankizumab 1200mg (Induction Period 1)) (met)

Result source: NCT03104413

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointJNJ-78934804risankizumab
Clinical remission (induction)—Trial running · NCT0757784342% vs 19.8%+22.2 vs placebo600 mg · wk 12 · n 191NCT03104413
26 other results
  • 28.8% vs 11.2% 600 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 45.2% vs 24.6% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 43.5% vs 21.7% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 40.3% vs 19.8% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 34.2% vs 11.2% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 41.6% vs 24.6% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 41% vs 21.7% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 34.6% vs 19.3% 600 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 42% vs 19.8% 600 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 43.5% vs 21.7% 600mg · wk 12 · n 336 · Phase 3 · secondary NCT03105128
  • 45.2% vs 24.6% 600mg · wk 12 · n 336 · Phase 3 · secondary NCT03105128
  • 20.9% vs 11.2% 600 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 17.3% vs 8% 600 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 18.4% vs 10.3% 600mg · wk 4 · n 336 · Phase 3 · secondary NCT03105128
  • 21% vs 9.1% 600mg · wk 4 · n 336 · Phase 3 · secondary NCT03105128
  • 39.8% vs 19.3% 1200 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 40.3% vs 19.8% 1200 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 41% vs 21.7% 1200mg · wk 12 · n 339 · Phase 3 · secondary NCT03105128
  • 41.6% vs 24.6% 1200mg · wk 12 · n 339 · Phase 3 · secondary NCT03105128
  • 19.4% vs 11.2% 1200 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 18.3% vs 8% 1200 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 18.9% vs 10.3% 1200mg · wk 4 · n 339 · Phase 3 · secondary NCT03105128
  • 21.2% vs 9.1% 1200mg · wk 4 · n 339 · Phase 3 · secondary NCT03105128
  • 36.6% vs 15.4% 600 mg IV · wk 12 · n 41 · Phase 2 · primary NCT02031276
  • 28% vs 15.4% 200 + 600 mg IV · wk 12 · n 82 · Phase 2 · primary NCT02031276
  • 19.5% vs 15.4% 200 mg IV · wk 12 · n 41 · Phase 2 · primary NCT02031276
Endoscopic response (induction)—Trial running · NCT0757784328.8% vs 11.2%+17.6 vs placebo600 mg · wk 12 · n 191NCT03104413
10 other results
  • 34.6% vs 19.3% 600 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 40.3% vs 12% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 40.3% vs 12% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 34.2% vs 11.2% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 39.8% vs 19.3% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 32.1% vs 12% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 32.1% vs 12% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 36.6% vs 12.8% 600 mg IV · wk 12 · n 41 · Phase 2 · secondary NCT02031276
  • 31.7% vs 12.8% 200 + 600 mg IV · wk 12 · n 82 · Phase 2 · secondary NCT02031276
  • 26.8% vs 12.8% 200 mg IV · wk 12 · n 41 · Phase 2 · secondary NCT02031276
Clinical remission (maintenance)—Trial running · NCT07577843—Trial running · NCT06063967
Endoscopic response (maintenance)—Trial running · NCT07577843—Trial running · NCT06063967

Clinical remission (induction)

JNJ-78934804
—Trial running · NCT07577843
risankizumab
42% vs 19.8%+22.2 vs placebo600 mg · wk 12 · n 191NCT03104413
26 other results
  • 28.8% vs 11.2% 600 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 45.2% vs 24.6% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 43.5% vs 21.7% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 40.3% vs 19.8% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 34.2% vs 11.2% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 41.6% vs 24.6% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 41% vs 21.7% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 34.6% vs 19.3% 600 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 42% vs 19.8% 600 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 43.5% vs 21.7% 600mg · wk 12 · n 336 · Phase 3 · secondary NCT03105128
  • 45.2% vs 24.6% 600mg · wk 12 · n 336 · Phase 3 · secondary NCT03105128
  • 20.9% vs 11.2% 600 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 17.3% vs 8% 600 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 18.4% vs 10.3% 600mg · wk 4 · n 336 · Phase 3 · secondary NCT03105128
  • 21% vs 9.1% 600mg · wk 4 · n 336 · Phase 3 · secondary NCT03105128
  • 39.8% vs 19.3% 1200 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 40.3% vs 19.8% 1200 mg · wk 12 · n 191 · Phase 3 · secondary NCT03104413
  • 41% vs 21.7% 1200mg · wk 12 · n 339 · Phase 3 · secondary NCT03105128
  • 41.6% vs 24.6% 1200mg · wk 12 · n 339 · Phase 3 · secondary NCT03105128
  • 19.4% vs 11.2% 1200 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 18.3% vs 8% 1200 mg · wk 4 · n 191 · Phase 3 · secondary NCT03104413
  • 18.9% vs 10.3% 1200mg · wk 4 · n 339 · Phase 3 · secondary NCT03105128
  • 21.2% vs 9.1% 1200mg · wk 4 · n 339 · Phase 3 · secondary NCT03105128
  • 36.6% vs 15.4% 600 mg IV · wk 12 · n 41 · Phase 2 · primary NCT02031276
  • 28% vs 15.4% 200 + 600 mg IV · wk 12 · n 82 · Phase 2 · primary NCT02031276
  • 19.5% vs 15.4% 200 mg IV · wk 12 · n 41 · Phase 2 · primary NCT02031276

Endoscopic response (induction)

JNJ-78934804
—Trial running · NCT07577843
risankizumab
28.8% vs 11.2%+17.6 vs placebo600 mg · wk 12 · n 191NCT03104413
10 other results
  • 34.6% vs 19.3% 600 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 40.3% vs 12% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 40.3% vs 12% 600mg · wk 12 · n 336 · Phase 3 · primary NCT03105128
  • 34.2% vs 11.2% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 39.8% vs 19.3% 1200 mg · wk 12 · n 191 · Phase 3 · primary NCT03104413
  • 32.1% vs 12% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 32.1% vs 12% 1200mg · wk 12 · n 339 · Phase 3 · primary NCT03105128
  • 36.6% vs 12.8% 600 mg IV · wk 12 · n 41 · Phase 2 · secondary NCT02031276
  • 31.7% vs 12.8% 200 + 600 mg IV · wk 12 · n 82 · Phase 2 · secondary NCT02031276
  • 26.8% vs 12.8% 200 mg IV · wk 12 · n 41 · Phase 2 · secondary NCT02031276

Clinical remission (maintenance)

JNJ-78934804
—Trial running · NCT07577843
risankizumab
—Trial running · NCT06063967

Endoscopic response (maintenance)

JNJ-78934804
—Trial running · NCT07577843
risankizumab
—Trial running · NCT06063967
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

JNJ-78934804: no structured comparison results are available for Crohn's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. JNJ-78934804: 0 of 4 rows · risankizumab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricrisankizumab
Dropout rate
1.9%600 mga
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 16 more results
—360 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—180 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
2.9%1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—600mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—360mg SC
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—180mg SC
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—600 mg IV
NCT02513459 · Phase 2 · registry result, not featured evidence
—180 mg SC
NCT02513459 · Phase 2 · registry result, not featured evidence
—600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
—600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
—180 mg SC
NCT02031276 · Phase 2 · registry result, not featured evidence
—200 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—600 mga
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 16 more results
—360 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—180 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
—600mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—360mg SC
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—180mg SC
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
—600 mg IV
NCT02513459 · Phase 2 · registry result, not featured evidence
—180 mg SC
NCT02513459 · Phase 2 · registry result, not featured evidence
—600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
—600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
—180 mg SC
NCT02031276 · Phase 2 · registry result, not featured evidence
—200 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
Serious AEs
4.9%600 mga
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 16 more results
4.8%360 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
4.9%180 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
4.4%1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
7.1%1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
7.2%600mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
4.4%360mg SC
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
4.5%180mg SC
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
3.8%1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
5.3%1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
6%1200mg IV
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
0%600 mg IV
NCT02513459 · Phase 2 · registry result, not featured evidence
35.4%180 mg SC
NCT02513459 · Phase 2 · registry result, not featured evidence
9.8%600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
10.9%600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
11.3%180 mg SC
NCT02031276 · Phase 2 · registry result, not featured evidence
24.4%200 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
600 mga
headache 5.3% (placebo 5.3%)
arthralgia 3.9% (placebo 3.9%)
nasopharyngitis 3.9% (placebo 5.3%)
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 16 more results
360 mg
arthralgia 2.4% (placebo 3.9%)
headache 2.4% (placebo 5.3%)
nausea 2.4% (placebo 4.8%)
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
180 mg
arthralgia 4.9% (placebo 3.9%)
crohn's disease 2.4% (placebo 6.3%)
headache 2.4% (placebo 5.3%)
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
1200 mg
headache 4.9% (placebo 5.3%)
arthralgia 4.4% (placebo 3.9%)
nasopharyngitis 3.9% (placebo 5.3%)
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
1200 mg
headache 7.1% (placebo 5.3%)
nausea 7.1% (placebo 4.8%)
crohn's disease 4.8% (placebo 6.3%)
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
600mg IV
headache 6.4% (placebo 4.3%)
nasopharyngitis 5.9% (placebo 2.7%)
nausea 4.3% (placebo 5.4%)
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
360mg SC
headache 4.4% (placebo 4.3%)
anaemia 2.9% (placebo 2.7%)
crohn's disease 1.5% (placebo 5.4%)
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
180mg SC
crohn's disease 3% (placebo 5.4%)
headache 1.5% (placebo 4.3%)
nasopharyngitis 1.5% (placebo 2.7%)
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
1200mg IV
nasopharyngitis 5.9% (placebo 2.7%)
headache 5.4% (placebo 4.3%)
nausea 3.5% (placebo 5.4%)
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
1200mg IV
headache 6.6% (placebo 4.3%)
anaemia 5.3% (placebo 2.7%)
nausea 3.9% (placebo 5.4%)
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
1200mg IV
headache 3% (placebo 4.3%)
anaemia 1.5% (placebo 2.7%)
nasopharyngitis 1.5% (placebo 2.7%)
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
600 mg IV
abdominal pain upper 25%
ear pain 25%
haematochezia 25%
NCT02513459 · Phase 2 · registry result, not featured evidence
180 mg SC
nasopharyngitis 30.8%
gastroenteritis 23.1%
fatigue 20%
NCT02513459 · Phase 2 · registry result, not featured evidence
600 mg IV
arthralgia 19.5% (placebo 10.3%)
headache 12.2% (placebo 12.8%)
abdominal pain 9.8% (placebo 12.8%)
NCT02031276 · Phase 2 · registry result, not featured evidence
600 mg IV
abdominal pain 10.9% (placebo 12.8%)
nasopharyngitis 7.9% (placebo 7.7%)
arthralgia 6.9% (placebo 10.3%)
NCT02031276 · Phase 2 · registry result, not featured evidence
180 mg SC
nasopharyngitis 14.5% (placebo 7.7%)
arthralgia 9.7% (placebo 10.3%)
headache 9.7% (placebo 12.8%)
NCT02031276 · Phase 2 · registry result, not featured evidence
200 mg IV
nausea 22% (placebo 10.3%)
abdominal pain 14.6% (placebo 12.8%)
arthralgia 14.6% (placebo 10.3%)
NCT02031276 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 6 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

risankizumab

Clinical Remission 42% (n=191) vs 19.8% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 26 more results
28.8% (n=191) vs 11.2% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
34.6% (n=191) vs 19.3% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
20.9% (n=191) vs 11.2% (n=187) placebo @ 4wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
42% (n=191) vs 19.8% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
17.3% (n=191) vs 8% (n=187) placebo @ 4wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
45.2% (n=336) vs 24.6% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
43.5% (n=336) vs 21.7% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
43.5% (n=336) vs 21.7% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
18.4% (n=336) vs 10.3% (n=175) placebo @ 4wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
45.2% (n=336) vs 24.6% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
21% (n=336) vs 9.1% (n=175) placebo @ 4wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
36.6% (n=41) vs 15.4% (n=39) placebo @ 12wk600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
28% (n=82) vs 15.4% (n=39) placebo @ 12wk200 + 600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
40.3% (n=191) vs 19.8% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
34.2% (n=191) vs 11.2% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
39.8% (n=191) vs 19.3% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
19.4% (n=191) vs 11.2% (n=187) placebo @ 4wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
40.3% (n=191) vs 19.8% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
18.3% (n=191) vs 8% (n=187) placebo @ 4wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
41.6% (n=339) vs 24.6% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
41% (n=339) vs 21.7% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
41% (n=339) vs 21.7% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
18.9% (n=339) vs 10.3% (n=175) placebo @ 4wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
41.6% (n=339) vs 24.6% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
21.2% (n=339) vs 9.1% (n=175) placebo @ 4wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
19.5% (n=41) vs 15.4% (n=39) placebo @ 12wk200 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
Endoscopic 28.8% (n=191) vs 11.2% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 10 more results
34.6% (n=191) vs 19.3% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
40.3% (n=336) vs 12% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
40.3% (n=336) vs 12% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
36.6% (n=41) vs 12.8% (n=39) placebo @ 12wk600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
31.7% (n=82) vs 12.8% (n=39) placebo @ 12wk200 + 600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
34.2% (n=191) vs 11.2% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
39.8% (n=191) vs 19.3% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
32.1% (n=339) vs 12% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
32.1% (n=339) vs 12% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
26.8% (n=41) vs 12.8% (n=39) placebo @ 12wk200 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
CDAI 36.6% (n=191) vs 20.9% (n=187) placebo @ 4wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 15 more results
59.5% (n=191) vs 30% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
36.6% (n=191) vs 20.9% (n=187) placebo @ 4wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
59.5% (n=191) vs 30% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
40.8% (n=336) vs 25.2% (n=175) placebo @ 4wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
59.7% (n=336) vs 36.7% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
40.8% (n=336) vs 25.2% (n=175) placebo @ 4wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
59.7% (n=336) vs 36.7% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
32.5% (n=191) vs 20.9% (n=187) placebo @ 4wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
60.7% (n=191) vs 30% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
32.5% (n=191) vs 20.9% (n=187) placebo @ 4wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
60.7% (n=191) vs 30% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
37.2% (n=339) vs 25.2% (n=175) placebo @ 4wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
64.9% (n=339) vs 36.7% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
37.2% (n=339) vs 25.2% (n=175) placebo @ 4wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
64.9% (n=339) vs 36.7% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
CDAI Response and Endoscopic 20.5% (n=191) vs 5.3% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 3 more results
30% (n=336) vs 5.7% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
23% (n=191) vs 5.3% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
23% (n=339) vs 5.7% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
Stool Frequency Remission 46.1% (n=191) vs 28.3% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 3 more results
54.2% (n=336) vs 29.8% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
48.7% (n=191) vs 28.3% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
54% (n=339) vs 29.8% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
Abdominal Pain Remission 58.1% (n=191) vs 36.4% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 3 more results
59.6% (n=336) vs 38.5% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
59.2% (n=191) vs 36.4% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
58.1% (n=339) vs 38.5% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
Endoscopic Remission 19.4% (n=191) vs 4.3% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 10 more results
19.4% (n=191) vs 4.3% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
24.2% (n=336) vs 9.1% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
24.2% (n=336) vs 9.1% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
19.5% (n=41) vs 2.6% (n=39) placebo @ 12wk600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
14.6% (n=82) vs 2.6% (n=39) placebo @ 12wk200 + 600 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
20.4% (n=191) vs 4.3% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
20.4% (n=191) vs 4.3% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
23.9% (n=339) vs 9.1% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
23.9% (n=339) vs 9.1% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
9.8% (n=41) vs 2.6% (n=39) placebo @ 12wk200 mg IV
NCT02031276 · Phase 2 · registry result, not featured evidence
Enhanced Clinical 45% (n=191) vs 31.6% (n=187) placebo @ 4wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 15 more results
61.8% (n=191) vs 39.1% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
45% (n=191) vs 31.6% (n=187) placebo @ 4wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
61.8% (n=191) vs 39.1% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
46% (n=336) vs 31% (n=175) placebo @ 4wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
62.8% (n=336) vs 41.9% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
46% (n=336) vs 31% (n=175) placebo @ 4wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
62.8% (n=336) vs 41.9% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
38.7% (n=191) vs 31.6% (n=187) placebo @ 4wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
59.2% (n=191) vs 39.1% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
38.7% (n=191) vs 31.6% (n=187) placebo @ 4wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
59.2% (n=191) vs 39.1% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
43.4% (n=339) vs 31% (n=175) placebo @ 4wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
64.3% (n=339) vs 41.9% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
43.4% (n=339) vs 31% (n=175) placebo @ 4wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
64.3% (n=339) vs 41.9% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
Ulcer-Free Endoscopy 13.8% (n=190) vs 4.3% (n=186) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 7 more results
13.8% (n=190) vs 4.3% (n=186) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
21% (n=336) vs 7.6% (n=173) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
21% (n=336) vs 7.6% (n=173) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
15.4% (n=189) vs 4.3% (n=186) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
15.4% (n=189) vs 4.3% (n=186) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
16.4% (n=339) vs 7.6% (n=173) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
16.4% (n=338) vs 7.6% (n=173) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
EIM Resolution 29.5% (n=100) vs 23.7% (n=97) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 7 more results
29.5% (n=100) vs 23.7% (n=97) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
38.1% (n=140) vs 20.5% (n=64) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
38.1% (n=140) vs 20.5% (n=64) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
37.1% (n=97) vs 23.7% (n=97) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
37.1% (n=97) vs 23.7% (n=97) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
43.7% (n=158) vs 20.5% (n=64) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
43.7% (n=158) vs 20.5% (n=64) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
CD-Related Hospitalization 3.1% (n=191) vs 11.2% (n=187) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 7 more results
3.1% (n=191) vs 11.2% (n=187) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
3.3% (n=339) vs 12% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
3.3% (n=336) vs 12% (n=175) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
2.1% (n=191) vs 11.2% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
2.1% (n=191) vs 11.2% (n=187) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
1.8% (n=339) vs 12% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
1.8% (n=339) vs 12% (n=175) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
Draining Fistula Closure 7.1% (n=14) vs 13.3% (n=15) placebo @ 12wk600 mg
responder rate · % of participants
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
show 7 more results
7.1% (n=14) vs 13.3% (n=15) placebo @ 12wk600 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
27.8% (n=18) vs 22.2% (n=9) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
27.8% (n=18) vs 22.2% (n=9) placebo @ 12wk600mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
43.8% (n=16) vs 13.3% (n=15) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
43.8% (n=16) vs 13.3% (n=15) placebo @ 12wk1200 mg
NCT03104413 · Phase 3 · Crohn's Disease · phase 3
29.2% (n=24) vs 22.2% (n=9) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3
29.2% (n=24) vs 22.2% (n=9) placebo @ 12wk1200mg
NCT03105128 · Phase 3 · Crohn's Disease · phase 3

+ 32 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JNJ-78934804's landscape · risankizumab's landscape